Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ischemia therapeutic agent

a technology of ischemia and therapeutic agents, applied in the field of ischemia therapeutic agents, can solve the problems of refractory infections, delayed wound healing, intense psychological and physical suffering of patients, etc., and achieve the effects of promoting vascularization, preventing reperfusion injury, and inhibiting fibrosis

Inactive Publication Date: 2008-12-25
TABATA +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides an ischemia therapeutic agent that contains vascularization induction factor and gelatin hydrogel. The gelatin hydrogel is made by alkaline hydrolysis treatment of collagen and has the following physical properties: an acidic gelatin with a zeta potential of about -15 to -20 mV. The gelatin can be obtained from various animal species such as cows, and it can be crosslinked with chemical crosslinking agents or heat treatment. The resulting gelatin hydrogel can be used to prepare implants or injectable preparations. The invention also provides a method for preparing a gelatin hydrogel in the form of spheres or particles. The technical effects of the invention include the ability to induce angiogenesis and improve blood flow in ischemic tissues."

Problems solved by technology

Although serious upper or lower extremity isohemic diseases as such are not lethal, the resulting amputation of an upper or lower extremity causes immense psychological and physical suffering for the patient.
Moreover, serious ischemia of the extremities not only causes poor circulation, but also causes delayed wound healing and refractory infections at the affected area, and for example, can cause infection of artificial blood vessels in patients who have undergone bypass surgery using artificial blood vessels, which can ultimately lead to a fatal outcome.
However, there are currently no known treatment methods for this condition that have demonstrated adequate therapeutic effects.
In addition, the application range of this treatment method is tending to expand to also include elderly patients and patients complicated with diseases involving other organs, for which it was difficult to apply this treatment in the past.
However, a large number of unsuccessful cases of have been reported due to increases in the patient population resulting from improved diagnostic techniques, and there have even been cases reported which have ultimately resulted to upper or lower extremity amputation.
Namely, in serious cases, the therapeutic effects of surgical treatment methods are only able to somewhat extend the period during which the extremities are able to be conserved, and their treatment results have been extremely poor.
On the other hand, although medicinal treatment methods primarily consist of promotion of collateral circulation through administration of circulation ameliorants such as vasodilators, there is currently no known treatment method for which adequate effects can be obtained.
However, this method has the shortcomings of the gene expression efficiency being low, and being unable to control the level or timing of gene expression.
In addition, there is also the problem of the expression of unknown effects resulting from gene insertion still not having been resolved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ischemia therapeutic agent
  • Ischemia therapeutic agent
  • Ischemia therapeutic agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

A. Preparation of bFGF-Containing Gelatin Hydrogel

[0059]Gelatin hydrogel containing bFGF was prepared according to the method described in WO 94 / 27630. More specifically, a mixture of alkaline-treated gelatin aqueous solution having an isoelectric point of 4.9 (10 wt %, 20 ml) and olive oil (5 ml) was preheated at 40° C. and stirred for 1 hour, and after removing the natural gelatin by cooling the prepared emulsion with ice, acetone was added followed by stirring for 1 hour at 4° C. The resulting gelatin particles were washed three times with acetone (4° C.) and then recovered by centrifugal separation (5000 rpm, 4° C., 5 minutes).

[0060]The resulting non-crosslinked gelatin particles (20 mg) were suspended in an aqueous solution of Tween 80 (0.1%, 20 ml) containing glutaraldehyde (0.13 wt %) and then stirred for 24 hours at 4° C. to carry out the crosslinking reaction. After recovering by centrifugal separation (5000 rpm, 4° C., 5 minutes), the particles were stored for 1 hour at 37...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention provides a ischemia therapeutic agent that contains vascularization induction factor and gelatin hydrogel, and gradually releases vascularization induction factor, which is useful in treating ischemia accompanying peripheral circulatory disorders etc. encountering as complications of arteriosclerosis obliterans, Buerger's disease, diabetes and collagen disease.

Description

TECHNICAL FIELD[0001]The present invention relates to a ischemia therapeutic agent that contains a vascularization induction factor and a gelatin hydrogel, and gradually releases vascularization induction factor.BACKGROUND ART[0002]In the field of vascular surgery, numerous cases have been reported involving serious ischemia of the upper or lower extremities caused by peripheral vasculitis associated with atherosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and collagen disease.[0003]Although serious upper or lower extremity isohemic diseases as such are not lethal, the resulting amputation of an upper or lower extremity causes immense psychological and physical suffering for the patient.[0004]Moreover, serious ischemia of the extremities not only causes poor circulation, but also causes delayed wound healing and refractory infections at the affected area, and for example, can cause infection of artificial blood vessels in patients who have undergone bypass surg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/39A61P9/10A61K38/01A61K38/18A61K47/42A61P9/00
CPCA61K9/0019A61K38/014A61K38/1825A61K47/42A61K2300/00A61K38/1833A61K38/1866A61P9/00A61P9/10
Inventor TABATAKOMEDA, MASASHI
Owner TABATA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com